Fundraising Fox
Xenon Pharmaceuticals
NASDAQ: XENE423 employees on LinkedIn · 5 known investors
Find your way into Xenon Pharmaceuticals
Sign up to see every warm intro you have to Xenon Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xenon Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
Founders & leadership
IM
DC
Darren ClineChief Commercial OfficerDarren Cline is Chief Commercial Officer at Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. Previously, he served as CEO of Epygenix Therapeutics, where he led a rare disease epilepsy portfolio through late-stage development.
AD
Andrea DiFabioChief Legal Officer and Corporate SecretaryAndrea DiFabio is Chief Legal Officer and Corporate Secretary of Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He brings experience in public company M&A, securities law, licensing, intellectual property matters, and pharmaceutical product commercialization.
JE
James EmpfieldExecutive Vice President, Drug DiscoveryJames Empfield held senior drug discovery and medicinal chemistry leadership roles at both biotech and pharmaceutical companies, including leading a research organization of over 200 scientists and establishing a medicinal chemistry group at a large pharma firm. He brings expertise in central nervous system, oncology, virology, and anti-inflammatory drug discovery programs.
CK
Chris KenneyChief Medical OfficerChris Kenney is a board-certified neurologist with extensive clinical research experience in academic and industry settings, including leadership roles in pharmaceutical drug development across multiple stages. He brings expertise in clinical development, product launches, and regulatory compliance, with deep experience across neurological and psychiatric disorders including epilepsy, depression, and movement disorders.
SM
MD
Matthew D. RonsheimChief Operating OfficerMatthew D. Ronsheim is Chief Operating Officer at Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He brings over 25 years of experience in biotechnology and pharmaceutical operations, with background spanning R&D, regulatory affairs, manufacturing, commercial strategy, and organizational leadership across discovery, clinical development, and commercialization phases.
RS
Robin SherringtonExecutive Vice President, Strategy and InnovationRobin Sherrington is Executive Vice President of Strategy and Innovation at Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He has held business development and scientific roles focused on strategic partnerships in biotechnology and pharmaceuticals.
Investors · 5
Archer Capital Grouplisted by Archer Capital GroupLos Angeles
How we know: Archer Capital Group's portfolio page · Not right? Tell us
Archer Venture Capitallisted by Archer Venture CapitalLos Angeles
How we know: Archer Venture Capital's portfolio page · Not right? Tell us
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · Not right? Tell us
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: a partner's Signal profile · Not right? Tell us
Valuation · disclosed
Disclosed events$122.2Mvaluation at IPONov 2014 · $9.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Xenon Pharmaceuticals do?
- Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
- Who are Xenon Pharmaceuticals's investors?
- Xenon Pharmaceuticals's investors include Archer Capital Group, Archer Venture Capital, Avoro Capital Advisors, Foresite Capital, New Enterprise Associates (NEA).